Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SHBG | P04278 | 2/20 | 0.49 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.49 |
| ▸ | SNCA | P37840 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821320 | 1.00 | CYP19A1 (0.78) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL2600419 | 0.87 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL42712 | 0.87 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL42713 | 0.87 | CYP19A1 (1.00) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL7884439 | 0.84 | CYP19A1 (0.70) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL1900489 | 0.81 | CYP19A1 (0.70) | CYP19A1ALDH1A1MAPK1BLMPMP22 | |
| SCHEMBL1900487 | 0.81 | CYP19A1 (0.70) | CYP19A1ALDH1A1MAPK1BLMPMP22 | |
| SCHEMBL5432268 | 0.80 | CYP19A1 (0.68) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL7884266 | 0.80 | CYP19A1 (0.68) | CYP19A1ALDH1A1LMNASHBGSERPINA6 | |
| SCHEMBL8980163 | 0.80 | CYP19A1 (0.68) | CYP19A1ALDH1A1LMNASHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340502-A2 | Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods | PHERIN CORPORATION (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020143001-A1 | Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods | BERLINER, MARTHA | 2002-10-03 | — | — | US | claimed |
| EP-0711169-A4 | ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORP (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0711169-A1 | ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1996-05-15 | — | — | EP | claimed |
| WO-1994028904-A1 | ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1994-12-22 | — | — | WO | claimed |
| EP-1340502-A2 | Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods | PHERIN CORPORATION (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20020143001-A1 | Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods | BERLINER, MARTHA | 2002-10-03 | — | — | US | disclosed |
| US-20020103391-A1 | Novel androstanes for inducing hypothalamic effects | BERLINER DAVID L (US) | 2002-08-01 | — | — | US | disclosed |
| EP-0711169-A4 | ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORP (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5969168-A | STIMULATE AUTONOMIC ACTIVITY | PHERIN CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5965552-A | ADMINISTERING ANDROSTA-4,16-DIEN-3-OL FOR TREATING TENSION, REDUCING ANXIETY; ADMINISTERING TO THE VOMERONASAL ORGAN OF INDIVIDUAL | PHERIN PHARMACEUTICALS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5883087-A | ADMINISTERING TO THE VOMERONASAL ORGAN OF SAID INDIVIDUAL ANDROSTA-4,16-DIEN-3.BETA.-OL. | PHERIN CORPORATION (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0783512-A4 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORP (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0783512-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0711169-A1 | ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1996-05-15 | — | — | EP | disclosed |
| WO-1996010031-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1994028904-A1 | ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143001-A1 | Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods | SHBG, NR5A1, MC2R | CYP19A1 10/4885ALDH1A1 1060/4885LMNA 4128/4885 |
| US-20020103391-A1 | Novel androstanes for inducing hypothalamic effects | FABP7, NR3C2, NR3C1 | CYP19A1 109/4885ALDH1A1 2386/4885LMNA 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.